Shengren Yang - Synmosa Biopharma Director
| 4114 Stock | TWD 34.40 0.40 1.15% |
Director
Yang Shengren was Director of Synmosa Biopharma Corporation since June 15, 2010. Yang also serves as Senior Special Assistant and Assistant General ManagerOperating Business of the Company. Yang holds a MBA from Tulane University, the United States. since 2010.
| Tenure | 14 years |
| Professional Marks | MBA |
| Phone | 886 2 8797 7100 |
| Web | https://www.synmosa.com.tw |
Synmosa Biopharma Management Efficiency
The company has return on total asset (ROA) of 0.0223 % which means that it generated a profit of $0.0223 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0894 %, meaning that it generated $0.0894 on every $100 dollars invested by stockholders. Synmosa Biopharma's management efficiency ratios could be used to measure how well Synmosa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | DIRECTOR Age | ||
| ChiangSung Fu | Professional Computer Technolog | N/A | |
Management Performance
| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 |
Synmosa Biopharma Leadership Team
Elected by the shareholders, the Synmosa Biopharma's board of directors comprises two types of representatives: Synmosa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synmosa. The board's role is to monitor Synmosa Biopharma's management team and ensure that shareholders' interests are well served. Synmosa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synmosa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChihHui Lin, GM, Chairman | ||
| Zen Young, Marketing HP | ||
| Hongqin Bai, Sr Officer | ||
| Banson Lin, Sr Distributors | ||
| Shengren Yang, Director | ||
| JiaXin Zhang, VP | ||
| HungChin Pai, VP Officer |
Synmosa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Synmosa Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 17.93 B | |||
| Shares Outstanding | 327.14 M | |||
| Shares Owned By Insiders | 25.42 % | |||
| Shares Owned By Institutions | 0.90 % | |||
| Price To Earning | 14.65 X | |||
| Price To Book | 3.09 X |
Pair Trading with Synmosa Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Synmosa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Synmosa Stock
Moving against Synmosa Stock
| 0.92 | 9904 | Pou Chen Corp | PairCorr |
| 0.85 | 2881A | Fubon Financial Holding | PairCorr |
| 0.77 | 2882B | Cathay Financial Holding | PairCorr |
| 0.69 | 4123 | Center Laboratories | PairCorr |
| 0.63 | 2881B | Fubon Financial Holding | PairCorr |
The ability to find closely correlated positions to Synmosa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Synmosa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Synmosa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Synmosa Biopharma to buy it.
The correlation of Synmosa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Synmosa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Synmosa Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Synmosa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.